Discovery May Lead to New Treatments for Crohn's Disease

Using a mouse model, researchers may have identified inflammatory cells that drive fibrosis in Crohn’s disease.

In a study published in Science Immunology, researchers used mice infected with a type of salmonella that mimics the symptoms of Crohn’s disease. They found that a mutation prevented fibrosis from developing after the mice were infected.

In fact, the mutation switched off a hormone receptor responsible for stimulating part of the body’s immune response, according to the study.

“We found what we think are the inflammatory cells that drive fibrosis,” said study co-author Kelly McNagny. “The gene that was defective in those cells is a hormone receptor, and there are drugs available that may be able to block that hormone receptor in normal cells and prevent fibrotic disease.”

Researchers believe these inflammatory cells may be the orphan nuclear receptor ROR alpha, and the group 3 innate lymphoid cells. In addition to those findings, researchers also believe their discovery could be used with other types of tissue that experience fibrosis.

“Fibrosis is a response to chronic inflammation, but it is also a process that occurs during normal ageing,” said lead study author Bernard Lo. “If you can reverse this, you’ve essentially found a way to promote regeneration rather than degeneration.”

Several conditions, such as chronic kidney disease, scarring from heart attacks, muscle degeneration, and liver cirrhosis all result in tissue fibrosis.

“We think that we can potentially block complications of all these age-related fibrotic diseases by dampening these particular inflammatory cell types,” McNagny said.

Researchers noted that the next step will be to test different drugs to find out if they can stop or reverse fibrosis in mice.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Blocking the interaction between interleukin-33 and regulatory T cells may serve as a new therapeutic target for cancers associated with chronic inflammatory diseases.
Top news of the day across the health care landscape.
Pulmonary arterial hypertension (PAH) is a rare, debilitating, and fatal disease. Therapies are available that can improve symptoms and slow clinical deterioration of PAH; however, these therapies are characterized by complex management needs. This activity will provide a disease state overview, summarize PAH treatments and recommendations for management, and incorporate updates from the recently published consensus documents from the 6th World Symposium on Pulmonary Hypertension.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.